ACHL vs. ALMS, OGI, LFCR, CGEN, LRMR, AMRN, CTNM, VIRI, ZYBT, and DRUG
Should you be buying Achilles Therapeutics stock or one of its competitors? The main competitors of Achilles Therapeutics include Alumis (ALMS), Organigram (OGI), Lifecore Biomedical (LFCR), Compugen (CGEN), Larimar Therapeutics (LRMR), Amarin (AMRN), Contineum Therapeutics (CTNM), Virios Therapeutics (VIRI), Zhengye Biotechnology (ZYBT), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry.
Achilles Therapeutics vs.
Achilles Therapeutics (NASDAQ:ACHL) and Alumis (NASDAQ:ALMS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, community ranking, risk and profitability.
Achilles Therapeutics received 2 more outperform votes than Alumis when rated by MarketBeat users. However, 100.00% of users gave Alumis an outperform vote while only 54.84% of users gave Achilles Therapeutics an outperform vote.
Alumis' return on equity of 0.00% beat Achilles Therapeutics' return on equity.
In the previous week, Alumis had 6 more articles in the media than Achilles Therapeutics. MarketBeat recorded 6 mentions for Alumis and 0 mentions for Achilles Therapeutics. Alumis' average media sentiment score of 1.22 beat Achilles Therapeutics' score of 0.00 indicating that Alumis is being referred to more favorably in the news media.
56.4% of Achilles Therapeutics shares are owned by institutional investors. 5.4% of Achilles Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Achilles Therapeutics presently has a consensus target price of $4.00, indicating a potential upside of 189.86%. Alumis has a consensus target price of $26.57, indicating a potential upside of 413.95%. Given Alumis' stronger consensus rating and higher probable upside, analysts plainly believe Alumis is more favorable than Achilles Therapeutics.
Summary
Alumis beats Achilles Therapeutics on 9 of the 12 factors compared between the two stocks.
Get Achilles Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Achilles Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ACHL) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ACHL Stock Alerts